<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02720445</url>
  </required_header>
  <id_info>
    <org_study_id>ATRI-002-NIC</org_study_id>
    <secondary_id>R01AG047992</secondary_id>
    <secondary_id>131918</secondary_id>
    <nct_id>NCT02720445</nct_id>
  </id_info>
  <brief_title>Memory Improvement Through Nicotine Dosing (MIND) Study</brief_title>
  <acronym>MIND</acronym>
  <official_title>Long-Term Nicotine Treatment of Mild Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alzheimer's Therapeutic Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to see if daily transdermal nicotine is able to produce a
      significant cognitive, clinical and functional improvement in participants with MCI. Neuronal
      nicotinic receptors have long been known to play a critical role in memory function in
      preclinical studies, with nicotine improving attention, learning, and memory function.

      The study will enroll 300 participants for a 2 year period. Participants will be randomized
      (50:50) to either the transdermal nicotine, beginning at 7mg/day, and increasing to 21mg/day,
      or placebo skin patch.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline of the Conners Continuous Performance Task (CPT) to Month 25</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Mild Cognitive Impairment - Clinical Global Impression of Change (MCI-CGIC) to Month 25</measure>
    <time_frame>2 years</time_frame>
    <description>The MCI-CGIC is the MCI version of the clinician's global impression of change. In this trial it will measure change in the participant's condition between the baseline visit and subsequent visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Cogstate Brief Battery (CBB) to Month 25</measure>
    <time_frame>2 years</time_frame>
    <description>This battery will be used for the purpose of assessing the cognitive status of the participants and will assist in documenting multiple domains of cognitive impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline in New York University (NYU) Paragraph Recall to Month 25</measure>
    <time_frame>2 years</time_frame>
    <description>This test measures immediate and delayed verbal recall of a brief story.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Clinical Dementia Rating Scale (CDR) - Sum of Boxes (SOB) to Month 25</measure>
    <time_frame>2 years</time_frame>
    <description>The is a clinical scale that rates the severity of dementia as absent, questionable, mild, moderate, or severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline in Geriatric Depression Scale (GDS) to Month 25</measure>
    <time_frame>2 years</time_frame>
    <description>This is a 30-item self-report assessment used to identify depression in the elderly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) to Month 25</measure>
    <time_frame>2 years</time_frame>
    <description>This scale is an inventory developed to assess functional performance in participantss with Alzheimer's disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Older Adult Self Report (OASR) / Older Adult Behavior Checklist (OABCL) to Month 25</measure>
    <time_frame>2 years</time_frame>
    <description>The OASR/OABCL is a general index of psychopathologic symptoms and signs that is specifically relevant to elderly individuals and is developmentally appropriate, covers a wide range of psychopathologic signs and symptoms, and functional measures. It allows multi-informant perspective (both patient and informant). The items are focused on common elderly emotional, functional, or medical problems. The OASR is completed by the participant and the companion OABCL is completed by the informant.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from Baseline in Cerebral Spinal Fluid (CSF) Biomarkers to Month 25</measure>
    <time_frame>2 years</time_frame>
    <description>CSF will be performed in approximately 50 participants each</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline of Volumetric Magnetic Resonance Imaging (vMRI) to Month 25</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Nicotine Transdermal Patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 participants will wear nicotine transdermal patches during waking hours. Active dose will titrate up from 3.5mg to 21mg in the first 6 weeks of treatment, remain at 21mg for 22.5 months, and then taper down in the final month of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Patch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>150 participants will wear matching placebo patches during waking hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Transdermal Patch</intervention_name>
    <description>21mg Nicotine transdermal patches worn during waking hours. Active dose will titrate up from 3.5mg to 21mg in the first 6 weeks of treatment, remain at 21mg for 22.5 months, and then taper down in the final month of treatment.</description>
    <arm_group_label>Nicotine Transdermal Patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Patch</intervention_name>
    <description>Matching placebo patches worn during waking hours.</description>
    <arm_group_label>Placebo Patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant must have a subjective memory concern as reported by participant, study
             partner, or clinician

          2. Abnormal memory function documented by scoring within the education adjusted ranges on
             the Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory
             Scale - Revised:

               -  less than or equal to 11 for 16 or more years of education

               -  less than or equal to 9 for 8 - 15 years of education

               -  less than or equal to 6 for 0 - 7 years of education

          3. Mini-Mental State Exam score between 24 and 30, inclusive

          4. Clinical Dementia Rating (CDR) Global = 0.5. Memory Box score must be at least 0.5

          5. General cognition and functional performance sufficiently preserved such that a
             diagnosis of Alzheimer's disease dementia cannot be made by the site physician at the
             time of the screening visit

          6. Age 55-90 (inclusive)

          7. Stable permitted medications for 4 weeks or longer as specified in Section 6,
             including:

             â€¢ Memantine and cholinesterase inhibitors are allowable if stable for 12 weeks prior
             to screen

          8. Geriatric Depression Scale score of less than or equal to 14

          9. Study Partner is available who has frequent contact with the participant (e.g. an
             average of 10 hours per week or more), and can accompany the participant to most
             visits to answer questions about the participant

         10. Adequate visual and auditory acuity to allow neuropsychological testing

         11. Good general health with no additional diseases/disorders expected to interfere with
             the study

         12. Participant is not pregnant, lactating, or of childbearing potential (i.e. women must
             be two years post-menopausal or surgically sterile)

         13. Completed six grades of education or has a good work history

         14. Must speak English fluently

        Exclusion Criteria:

          1. Regular use of tobacco products within the past year, such as smoking (cigarettes,
             pipes, cigars, etc.) or use of other nicotine products (chewing tobacco, e-cigarettes,
             nicotine patches, gum, sprays, etc.).

          2. Any significant neurologic disease such as Alzheimer's disease dementia, Parkinson's
             disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus,
             brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma,
             multiple sclerosis, or history of significant head trauma followed by persistent
             neurologic deficits or known structural brain abnormalities.

          3. Major depression, bipolar disorder as described in DSM-V within the past 1 year or
             psychotic features, agitation or behavioral problems within 3 months, which could lead
             to difficulty complying with the protocol

          4. History of schizophrenia (DSM V criteria)

          5. History of alcohol or substance abuse or dependence within the past 2 years (DSM V
             criteria)

          6. Clinically significant or unstable medical condition, including uncontrolled
             hypertension, uncontrolled diabetes, or significant cardiac, pulmonary, renal,
             hepatic, endocrine, or other systemic disease in the opinion of the Investigator, may
             either put the participant at risk because of participation in the study, or influence
             the results, or the participant's ability to participate in the study.

          7. Has had a history within the last 5 years of a primary or recurrent malignant disease
             with the exception of non-melanoma skin cancers, resected cutaneous squamous cell
             carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ
             prostate cancer with normal prostate-specific antigen post-treatment

          8. Clinically significant abnormalities in B12 or TFTs (Thyroid Function Tests) that
             might interfere with the study. A low B12 is exclusionary, unless the required
             follow-up labs (homocysteine (HC) and methylmalonic acid (MMA)) indicate that it is
             not physiologically significant.

          9. Clinically significant abnormalities in screening laboratories or ECG.

         10. Residence in skilled nursing facility.

         11. Use of any excluded medication as described in the protocol, including:

               -  Use of centrally acting anti-cholinergic drugs

               -  Use of any investigational drugs within 30 days or 5 half-lives, whichever is
                  longer, prior to screening.

         12. For CSF sub-study participants, a current blood clotting or bleeding disorder, or
             significantly abnormal PT or PTT (partial thromboplastin time) at screening

         13. For MRI sub-study participants, contraindications for MRI studies, including
             claustrophobia, the presence of metal (ferromagnetic) implants, or cardiac pacemaker.

         14. Patients whom the Site PI deems to be otherwise ineligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Aisen, MD</last_name>
    <role>Study Director</role>
    <affiliation>USC Alzheimer's Therapeutic Research Institute (ATRI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Newhouse, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ATRI Recruitment</last_name>
    <email>mind-participate@usc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Perseverance Research Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85254</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Christians</last_name>
      <phone>480-471-6132</phone>
      <email>lchristians@prcresearcheducation.com</email>
    </contact>
    <investigator>
      <last_name>Allan Block, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Arkansas Veterans Healthcare System</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kalpana Padala</last_name>
      <phone>501-257-2044</phone>
      <email>Kalpana.padala@va.gov</email>
    </contact>
    <investigator>
      <last_name>Kalpana Padala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Rancho Los Amigos</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>William Shankle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sharp Mesa Vista Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Barder</last_name>
      <phone>858-836-8350</phone>
      <email>joshua.barder@sharp.com</email>
    </contact>
    <investigator>
      <last_name>Michael Plopper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Syrentis Clinical Research</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebeca Sanchez</last_name>
      <phone>714-542-3008</phone>
      <email>rsanchezCRC@gmail.com</email>
    </contact>
    <investigator>
      <last_name>John Duffy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Connecticut Medical Group</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Morsey</last_name>
      <phone>203-748-2551</phone>
      <phone_ext>377</phone_ext>
      <email>dawnmarie.morsey@wchn.org</email>
    </contact>
    <investigator>
      <last_name>Samuel Markind, MD, FAAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>200072145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Bassett</last_name>
      <phone>202-687-2352</phone>
      <email>mjb438@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Raymond Scott Turner, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JEM Research Institute</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belinda Russell</last_name>
      <phone>561-968-2933</phone>
    </contact>
    <investigator>
      <last_name>Mark Goldstein, MD, CPI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jetliza Lesmes</last_name>
      <phone>561-381-9060</phone>
      <email>jlesmes@brainmattersresearch.com</email>
    </contact>
    <investigator>
      <last_name>Mark Brody, MD, CPI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Jewish Health Systems</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Diaz</last_name>
      <phone>305-514-8710</phone>
      <email>Ediaz1@miamijewishhealth.org</email>
    </contact>
    <investigator>
      <last_name>Marc Agronin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34997</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jetliza Lesmes</last_name>
      <phone>561-381-9060</phone>
      <email>jlesmes@ergclinical.com</email>
    </contact>
    <investigator>
      <last_name>Mark Brody, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University Movement and Memory Disorders</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Jackson</last_name>
      <phone>706-721-4152</phone>
      <email>paujackson@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>John Morgan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana Freund</last_name>
      <phone>208-955-9030</phone>
      <phone_ext>2</phone_ext>
      <email>afreund@acr-research.com</email>
    </contact>
    <investigator>
      <last_name>Mark Alan Turner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>606113010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittanie Muse</last_name>
      <phone>312-503-5674</phone>
      <email>brittanie.muse@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Ian Grant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Ekstam-Smith</last_name>
      <phone>319-353-5158</phone>
      <email>karen-ekstam@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Delwyn Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cypress Medical Research Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Acadia Hospital</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krysta Anderson</last_name>
      <email>keanderson@emhs.org</email>
    </contact>
    <investigator>
      <last_name>Clifford Singer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Donald S. Marks, MD, PC</name>
      <address>
        <city>Plymouth</city>
        <state>Massachusetts</state>
        <zip>02360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelby Lydon</last_name>
      <phone>508-746-5060</phone>
      <email>shelbyl@dsmmdpc.com</email>
    </contact>
    <investigator>
      <last_name>Donald Marks, MD, PC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bronson Lakeview Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49079</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Cognitive and Research Center of New Jersey</name>
      <address>
        <city>Springfield</city>
        <state>New Jersey</state>
        <zip>07081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michelle Papka, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Memory Research Institute of New Jersey</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sanjiv Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Prestopnik</last_name>
      <phone>505-272-3735</phone>
      <email>jprestopnik@salud.unm.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Rosenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clarity Clinical Research</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Hall</last_name>
      <phone>315-760-5905</phone>
      <phone_ext>702</phone_ext>
      <email>cshall@clarityclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Karl Hafner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University at Buffalo (UBMD)</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Connie Brand</last_name>
      <phone>716-323-0549</phone>
      <email>conniebr@buffalo.edu</email>
    </contact>
    <investigator>
      <last_name>Kinga Szigeti, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>100166055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anaztasia Ulysse</last_name>
      <phone>212-263-0771</phone>
      <email>Anaztasia.Ulysse@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Arjun Vijay Masurkar, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>100296552</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Ardolino</last_name>
      <phone>212-241-0438</phone>
      <email>allison.ardolino@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Clara Li, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrative Clinical Trials</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khatuna Tsotsoria</last_name>
      <phone>718-444-7774</phone>
      <phone_ext>122</phone_ext>
      <email>khatuna.tsotsoria@iclinicaltrials.net</email>
    </contact>
    <investigator>
      <last_name>Inna Yuryev-Golger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Dillenbeck</last_name>
      <phone>315-464-3285</phone>
      <email>GeriResearch@upstate.edu</email>
    </contact>
    <investigator>
      <last_name>Sharon Brangman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Icenhour</last_name>
      <phone>614-293-6882</phone>
      <email>Jennifer.icenhour@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas Scharre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central States Research (formerly Tulsa Clinical Research)</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Lisenbee</last_name>
      <phone>918-955-4222</phone>
      <email>ChristyL@centralstatesresearch.com</email>
    </contact>
    <investigator>
      <last_name>Michael Karathanos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Brain and Spine Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynette Currie</last_name>
      <phone>503-216-1034</phone>
      <email>lynette.currie@providence.org</email>
    </contact>
    <investigator>
      <last_name>Ho-Yann Jong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LeHigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Orzel</last_name>
      <phone>610-402-8447</phone>
      <email>Andrew.Orzel@lvhn.org</email>
    </contact>
    <investigator>
      <last_name>Alison Walsh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard Kishel</last_name>
      <phone>717-531-0003</phone>
      <phone_ext>289860</phone_ext>
      <email>lkishel@pennstatehealth.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Eslinger, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roper St. Francis Hospital</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>294011113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Lapp</last_name>
      <phone>843-724-2214</phone>
      <email>allison.lapp@rsfh.com</email>
    </contact>
    <investigator>
      <last_name>Jacobo Mintzer, MD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Clinic, P.C.</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Sparks</last_name>
      <phone>901-866-9252</phone>
      <email>rsparks@neuroclinic.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Arnold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Boegel</last_name>
      <phone>615-875-0955</phone>
      <email>amy.r.boegel@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Patricia Serrano-Andrews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Garrett</last_name>
      <phone>713-441-9484</phone>
      <email>jmgarrett@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Masdeu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Glenn Biggs Institute at the University of Texas Health</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Saklad</last_name>
      <phone>210-567-8229</phone>
      <email>SakladA@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Sudha Seshadri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Bradford</last_name>
      <phone>801-585-9450</phone>
      <email>anna.bradford@utah.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Langenecker, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington / VA Puget Sound</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Ranta</last_name>
      <phone>206-764-2339</phone>
      <email>rantaa@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Elaine Peskind, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Memory and Brain Wellness Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yeung Tutterrow</last_name>
      <phone>206-897-6350</phone>
      <email>ylt2@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Persenaire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingfisher Cooperative, LLC</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Karschney</last_name>
      <phone>509-747-5615</phone>
      <email>VK@Kingfishercoop.com</email>
    </contact>
    <investigator>
      <last_name>David Greeley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice (Yanmin) Li</last_name>
      <phone>608-263-4290</phone>
      <email>ali@clinicaltrials.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Sanjay Asthana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nia.nih.gov/alzheimers</url>
    <description>Alzheimer's Disease Education and Referral (ADEAR) Center. The ADEAR Center is a service of the National Institute on Aging (NIA).</description>
  </link>
  <link>
    <url>http://keck.usc.edu/atri/research/studies/</url>
    <description>Alzheimer's Therapeutic Research Institute (ATRI). ATRI is the Coordinating Center for the MIND study.</description>
  </link>
  <link>
    <url>http://mindstudy.org/</url>
    <description>MIND study public website</description>
  </link>
  <reference>
    <citation>Newhouse PA, Potter A, Corwin J, Lenox R. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology. 1994 Apr;10(2):93-107.</citation>
    <PMID>8024677</PMID>
  </reference>
  <reference>
    <citation>Newhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, Pfaff A, Wilkins H, Howard D, Levin ED. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology. 2012 Jan 10;78(2):91-101. doi: 10.1212/WNL.0b013e31823efcbb.</citation>
    <PMID>22232050</PMID>
  </reference>
  <reference>
    <citation>Dumas J, Hancur-Bucci C, Naylor M, Sites C, Newhouse P. Estrogen treatment effects on anticholinergic-induced cognitive dysfunction in normal postmenopausal women. Neuropsychopharmacology. 2006 Sep;31(9):2065-78. Epub 2006 Feb 15.</citation>
    <PMID>16482084</PMID>
  </reference>
  <reference>
    <citation>Newhouse PA, Dumas J, Hancur-Bucci C, Naylor M, Sites CK, Benkelfat C, Young SN. Estrogen administration negatively alters mood following monoaminergic depletion and psychosocial stress in postmenopausal women. Neuropsychopharmacology. 2008 Jun;33(7):1514-27. Epub 2007 Aug 15.</citation>
    <PMID>17700646</PMID>
  </reference>
  <reference>
    <citation>Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL, Weingartner H, Mellow A, Murphy DL. Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology (Berl). 1988;95(2):171-5.</citation>
    <PMID>3137593</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 22, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2016</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Paul Aisen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Nicotine</keyword>
  <keyword>Transdermal Patch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

